Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
prostate cancer |
integrating analysis of sequence features and gene expression profiles |
prostate cancer |
up-regulated |
N/A |
sub-cellular localization-dependent function |
26975529 |
|
gastric cancer |
knockdown of TUG1 repressed GC proliferation |
non-small cell lung cancer |
up-regulated |
N/A |
TUG1 was associated with PRC2 |
26913601 |
|
Huntington's disease |
N/A |
N/A |
N/A |
expression |
TUG1 is upregulated in Huntington's disease brains, which is from the reanalysis of the Affymetrix U133A and B microarray data on normal and HD brains in this review. |
22202438 |
LncRNADisease
|
Huntington's disease |
N/A |
N/A |
N/A |
expression |
LncRNAs TUG1 (necessary for retinal development), and NEAT-1 (a structural component of nuclear paraspeckles) are upregulated in HD caudate, while the brain-specific tumor-suppressor MEG3 is downregulated in HD. |
23346095 |
LncRNADisease
|
bladder cancer |
N/A |
N/A |
N/A |
expression |
Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs |
24006935 |
LncRNADisease
|
bladder cancer |
N/A |
N/A |
N/A |
regulation |
Putative diagnostic and prognostic marker; oncogene |
24373479 |
LncRNADisease
|
osteosarcoma |
qPCR etc. |
osteosarcoma tissue, cell lines (U2OS etc.) |
up-regulated |
N/A |
We found significantly higher TUG1 and n377360 expression levels in osteosarcoma tissues compared with matched non-tumorous tissues. Suppression of TUG1 and n377360 expression by siRNA significantly impaired the cell proliferation potential of osteosarcoma cells. Furthermore, inhibition of TUG1 expression significantly promoted osteosarcoma cell apoptosis. The overexpression of TUG1 and n377360 in osteosarcoma specimens and the functional role of TUG1 and n377360 regarding cell proliferation and apoptosis in an osteosarcoma cell line provided evidence that the use of TUG1 or n377360 may be a viable but an as yet unexplored therapeutic strategy in tumors that over express these factors. |
23725133 |
Lnc2Cancer
|
multiple myeloma |
qPCR etc. |
blood (plasma) |
up-regulated |
N/A |
In our study, TUG1 levels were investigated in cell free plasma samples and higher expression was only observed in the MM group although correlation with disease state was observed both in the CLL and MM groups. |
24583225 |
LncRNADisease Lnc2Cancer
|
glioma |
qPCR etc. |
cell lines(U251, U87) |
down-regulated |
expression |
MEG3 and ST7OT1 are up-regulated in both cell lines under apoptosis induced using both agents. The induction of GAS5 is only clearly detected during DOX-induced apoptosis, whereas the up-regulation of neat1 and MIR155HG is only found during RES-induced apoptosis in both cell lines. However, TUG1, BC200 and MIR155HG are down regulated when necrosis is induced using a high dose of DOX in both cell lines. |
25645334 |
Lnc2Cancer
|
urothelial carcinoma of the bladder |
qPCR, knockdown etc. |
cell lines (T24, 5637 etc. |
up-regulated |
expression |
Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. |
22961206 |
LncRNADisease Lnc2Cancer
|
esophageal squamous cell carcinoma |
qPCR, knockdown, FCA etc. |
ESCC tissue |
up-regulated |
interaction |
TUG1 was significantly overexpressed in ESCC tissues compared with paired adjacent normal tissues, and high expression level of TUG1 was associated with family history and upper segment of esophageal cancer. Further, in vitro silencing TUG1 via siRNA inhibited the proliferation and migration of ESCC cells and blocked the progression of cell cycle. |
25366138 |
Lnc2Cancer
|
non-small cell lung cancer |
qPCR, Western blot, Luciferase reporter assay, knockdown etc. |
cell lines (A549, SK-MES-1, NCI-H1299 etc.) |
down-regulated |
regulation |
P53-regulated?long?non-coding?RNA?TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. |
24853421 |
LncRNADisease Lnc2Cancer
|
bladder cancer |
qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. |
bladder cancer tissue, |
up-regulated |
interaction |
We confirmed that TUG1 was overexpressed in bladder cancer tissues and established cell lines. Knockdown of TUG1 inhibited bladder cancer cell metastasis both in vitro and in vivo. Furthermore, we found that TUG1 promoted cancer cell invasion and radioresistance through inducing epithelial-to-mesenchymal transition (EMT). Interestingly, TUG1 decreased the expression of miR-145 and there was a reciprocal repression between TUG1 and miR-145 in an Argonaute2-dependent manner. ZEB2 was identified as a down-stream target of miR-145 and TUG1 exerted its function through the miR-145/ZEB2 axis. |
26318860 |
Lnc2Cancer
|
hepatocelluar carcinoma |
qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. |
HCC tissue, cell lines (HepG2, MHCC-97H, Hep3B) |
up-regulated |
interaction |
TUG1 expression was up-regulated in HCC tissues and the higher expression of TUG1 was significantly correlated with tumor size and Barcelona Clinic Liver Cancer (BCLC) stage. Moreover, silencing of TUG1 expression inhibited HCC cell proliferation, colony formation, tumorigenicity and induced apoptosis in HCC cell lines. We also found that TUG1 overexpression was induced by nuclear transcription factor SP1 and TUG1 could epigeneticly repress Kruppel-like factor 2 (KLF2) transcription in HCC cells by binding with PRC2 and recruiting it to KLF2 promoter region. |
26336870 |
Lnc2Cancer
|
colorectal cancer |
quantitative real-time PCR |
cultured representative CRC cell lines and 120 CRC patients |
up-regulated |
N/A |
increased their colony formation, migration, and invasion in vitro |
26856330 |
|
glioma |
quantitative RT-PCR, Annexin V/PI staining and cell counting kit-8 assays |
glioma tissues |
down-regulated |
interaction |
The dysregulation of taurine upregulated gene 1 affected the apoptosis and cell proliferation of glioma cells. Taurine upregulated gene 1 promoted cell apoptosis of glioma cells by activating caspase-3 and -9-mediated intrinsic pathways and inhibiting Bcl-2-mediated anti-apoptotic pathways, acting as a tumor suppressor in human glioma. |
26748401 |
|
|